



## **Abilita Bio adds Tom Boone to Scientific Advisory Board**

*Tom Boone brings deep expertise in therapeutic antibody discovery and development*

**SAN DIEGO, May 20, 2019** – [Abilita Bio, Inc.](#) today announced the appointment of Tom Boone to their Scientific Advisory Board.

“Tom is a world-renowned expert in biologics discovery and development. His guidance will be critical as we continue to build our internal pipeline and position ourselves as the leader in membrane protein-targeted therapeutics discovery” said Mauro Mileni, CEO of Abilita Bio.

Tom Boone has more than 37 years of accomplishments in the discovery and development of protein therapeutics. He worked at Amgen for 28 years and served in positions of increasing responsibility in growing Amgen Protein Sciences to an organization of over 300 researchers across five different sites while maintaining a long tradition of industry excellence. His career at Amgen began in 1981 as a bench scientist with the isolation and cDNA cloning of novel cytokines and growth factors including G-CSF. He was also responsible for purifying many of Amgen’s recombinant proteins. Tom’s responsibilities grew from Scientist to Director and he developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical applications. His continuing success led to leadership of all research protein technologies, and the evolution of Protein Sciences as an independent organization. Tom was the first Vice President of Amgen Protein Science and his teams were responsible for the majority of the current Amgen product portfolio and late stage clinical programs. Tom was the lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized. Tom has recently helped start several companies and has helped them license in clinical stage molecules. He is also currently a consultant or scientific advisor for more than 25 companies.

### **About Abilita Bio, Inc.**

Abilita Bio, Inc. was founded in 2014, and is an innovation-driven biotechnology company focused on leveraging its EMP™ platform and deep membrane protein expertise to enable the drug discovery and development. The company has established several research collaborations with global pharma and biotech partners focused on supporting their drug discovery programs, and has formed multiple strategic partnerships to build its internal R&D pipeline.